HUTCHMED (China) (HMDCF) Total Debt (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Total Debt came in at $94.5 million in Q2 2026, up 1.14% year-over-year from $93.4 million in Q2 2025, and up 1.45% quarter-over-quarter from $93.2 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Total Debt (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Total Debt for 12 consecutive years, with $94.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Debt rose 1.14% year-over-year to $94.5 million in Q2 2026; TTM through Jun 2026 was $94.5 million, a 1.14% increase from a year earlier, with the FY2025 full-year figure at $93.2 million, up 12.5% from the prior year.
- Total Debt was $94.5 million for Q2 2026 at HUTCHMED (China), up from $93.2 million in the prior quarter.
- Over five years, Total Debt peaked at $94.5 million in Q2 2026 and troughed at $2.5 million in Q2 2022.
- A 5-year average of $67.6 million and a median of $82.1 million in 2024 frame the typical range for Total Debt.
- Across the five-year window, Total Debt plunged 90.92% in 2022 and soared 1597.74% in 2023, its largest moves.
- Over 5 years, Total Debt stood at $38.3 million in 2022, then jumped by 107.12% to $79.3 million in 2023, then advanced by 4.36% to $82.8 million in 2024, then climbed by 12.5% to $93.2 million in 2025, then gained by 1.45% to $94.5 million in 2026.
- The last three Total Debt figures came in at $94.5 million (Q2 2026), $93.2 million (Q4 2025), and $93.4 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 62.75 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 28.66 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 8.09 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 94.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94.51 Mn |
| Dec 31, 2025 | 93.16 Mn |
| Jun 30, 2025 | 93.44 Mn |
| Dec 31, 2024 | 82.81 Mn |
| Jun 30, 2024 | 82.10 Mn |
| Dec 31, 2023 | 79.34 Mn |
| Jun 30, 2023 | 42.10 Mn |
| Dec 31, 2022 | 38.31 Mn |
| Jun 30, 2022 | 2.48 Mn |
| Dec 31, 2021 | 28.82 Mn |
| Jun 30, 2021 | 27.31 Mn |
| Mar 31, 2021 | 26.87 Mn |
| Dec 31, 2020 | 54.12 Mn |
| Jun 30, 2020 | 26.84 Mn |
| Dec 31, 2019 | 27.18 Mn |
| Sep 30, 2019 | 1.50 Mn |
| Jun 30, 2019 | 2.80 Mn |
| Mar 31, 2019 | 34.18 Mn |
| Dec 31, 2018 | 33.68 Mn |
| Jun 30, 2018 | 37.38 Mn |